Home
Explore Technologies
Stanford OTL
The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.
Contact
|
Explore Technologies
New Light Control Mechanism (NpHR) That Inhibits Neural Activity
Stanford Reference:
06-398
Abstract
The inventors have identified and developed an archaeal light-driven chloride pump (NpHR) from Natronomonas pharaonis for temporally precise optical inhibition of neural activity. NpHR allows either knockout of single action potentials, or sustained blockade of spiking. NpHR is compatible with ChR2, the previous optical excitation technology from their laboratory (Stanford Docket
S05-170
), in that the two opposing probes operate at similar light powers but with well-separated action spectra. NpHR, like ChR2, functions in mammals without exogenous cofactors, and the two probes can be integrated with calcium imaging in mammalian brain tissue for bidirectional optical modulation and readout of neural activity. Likewise, NpHR and ChR2 can be targeted together to Caenorhabditis elegans muscle and cholinergic motor neurons to control locomotion bidirectionally. NpHR and ChR2 form a complete system for multimodal, high-speed, genetically targeted, all-optical interrogation of living neural circuits.
Additional optical control of neural circuitry using NpHR is described in Stanford Docket S06-398A.
Stage of Research
The inventors have developed eNpHR (enhanced NpHR), an improved version of NpHR for safe expression at high levels under strong promoters and with augmented inhibitory function
in vitro
and
in vivo
.
Applications
Optical inhibition of neural activity for therapeutic and research purposes
Advantages
When combined with the engineered Channelrhodopsin ChR2, the NpHR/ChR2 system enables rapid bidirectional control of neurons on the timescale of milliseconds, thus enabling emulation or alteration of the neural code. These fast genetically based, neural-spike-controlling technologies powerfully augment existing tools for interrogating neural systems.
Publications
US Patent Application:
12/041,628
Feng Zhang, Li-Ping Wang, Martin Brauner, Jana F. Liewald, Kenneth Kay, Natalie Watzke, Phillip G. Wood, Ernst Bamberg, Georg Nagel, Alexander Gottschalk & Karl Deisseroth.
"Multimodal fast optical interrogation of neural circuitry"
Nature
446, 633-639 (5 April 2007)
Gradinaru V, Thompson KR, Deisseroth K.
"eNpHR: a Natronomonas halorhodopsin enhanced for optogenetic applications."
,
Brain Cell Biol.
2008 Aug;36(1-4):129-39. Epub 2008 Aug 2.
PCT Application: "Systems, Methods and Compositions for Optical Stimulation of Target Cells" (
W0/2008/106694
)
Related Web Links
Deisseroth Lab
Innovators & Portfolio
Karl Deisseroth
more technologies from Karl Deisseroth »
Viviana Gradinaru
more technologies from Viviana Gradinaru »
Feng Zhang
more technologies from Feng Zhang »
Patent Status
Published Application: 20090093403
Published Application: 20110301529
Published Application: 20140113367
Published Application: 20160175607
Published Application: 20180050219
Published Application: 20190224493
Issued : 9,757,587 (USA)
Issued : 9,284,353 (USA)
Issued : 9,855,442 (USA)
Issued : 10,589,123 (USA)
Date Released
10/8/2020 12:00
Licensing Contact
Evan Elder, Associate Director, Licensing and Strategic Alliances, Physica
650-725-9558 (Mobile)
Request Info
92-045
Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
93-077
A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)
95-006
G-Protein-Linked Receptor-Transfected Lymphoid Cell as Tools for Drug Discovery and for Cellular Therapeutics
more technologies »
Related Keywords
ion channels
epilepsy
MD: neurology
MD: neurology: neuromodulation
neuronal circuits
LS: General Therapeutic: Psychiatric Diseases
neuroscience
parkinson's disease
screening
seizure
LS: general therapeutic: CNS (neurology / central nervous system)
Coulter
06-398
therapeutic